The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.
 
James M. G. Larkin
Research Funding - Novartis (Inst); Pfizer (Inst)
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Merck
 
Keith Flaherty
Stock and Other Ownership Interests - Clovis Oncology; Loxo
Consulting or Advisory Role - Amgen; Genentech; GlaxoSmithKline; Lilly; Merck; Momenta Pharmaceuticals; Novartis; Oncoceutics; Sanofi; Viralytics
Research Funding - Novartis; Sanofi
Travel, Accommodations, Expenses - GlaxoSmithKline; Sanofi
 
Grant A. McArthur
Consulting or Advisory Role - Provectus
Research Funding - Celgene; Pfizer; Ventana Medical Systems
Travel, Accommodations, Expenses - Novartis; Roche
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche/Genentech; Ventana Medical Systems
Research Funding - Bristol-Myers Squibb; Roche/Genentech; Ventana Medical Systems
 
Brigitte Dréno
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; GlaxoSmithKline; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Karl D. Lewis
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
 
Paul B. Chapman
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Momenta Pharmaceuticals; Provectus
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Momenta Pharmaceuticals; Provectus
Research Funding - Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Edward Francis Mckenna
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Qian Zhu
Employment - Genentech
 
Yong Mun
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; MedImmune; MELA Sciences; Merck Serono; Merck Sharp & Dohme; Novartis; OncoSec; Roche